CRISPR/Cas13-RNA targeting therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CRISPR/Cas13-RNA targeting therapy, covering 2024-10-02 to 2024-10-02. Get the full timeline:
Most recent: Clinical Trial Update: Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial [Phase 1]